<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00675558</url>
  </required_header>
  <id_info>
    <org_study_id>AAAC0355</org_study_id>
    <secondary_id>R01DK072526</secondary_id>
    <nct_id>NCT00675558</nct_id>
  </id_info>
  <brief_title>Bariatric Surgery for Morbid Obesity</brief_title>
  <official_title>Bariatric Surgery for Morbid Obesity: Clinical and Pathophysiologic Consequences</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite progress in understanding the pathophysiology of obesity, current strategies for its
      medical management remain largely ineffective. Most efforts have focused on reducing caloric
      intake or increasing energy expenditure, either through behavior modification (e.g. dieting,
      regular exercise) alone, or augmented by pharmacologic efforts to decrease appetite, inhibit
      fat absorption, or alter metabolism. Bariatric surgery remains the only proven long term
      treatment of morbid obesity.

      Super morbidly obese (SMO: Body Mass Index (BMI) &gt; 50) and super super morbidly obese (SSMO:
      BMI &gt; 60) patients lose considerable weight, but stabilize at Body Mass Indexes (BMIs) that
      are still obese or even morbidly obese after risking considerable morbidity and/or mortality.
      Among commonly performed bariatric surgeries, a laparoscopic two-stage procedure, in which an
      initial restrictive procedure is followed after a weight loss of ~100 lbs by a more complex
      procedure that creates malabsorption, is gaining interest. Initial studies have demonstrated
      very good long-term weight loss with minimal morbidity, and no operative mortality in these
      high risk patients.

      Availability of biospecimens obtained at each stage of this protocol will allow participating
      scientists a unique opportunity to test in human tissues hypotheses developed in animals.
      Studies proposed under this application focus on fatty acids and overall fat disposition in
      fat depots (adipose tissue) of your body, and the role of adipose tissue hormones and
      inflammatory processes in obesity and its associated health related issues.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite rapidly growing interest in the pathogenesis of the obesity epidemic, the
      pathophysiology of obesity remain poorly understood. While studies in animals have yielded
      many insights, it has become clear that human obesity differs in important ways from that in
      rodents. Bariatric surgery offers better outcomes, but in the highest grades of obesity
      (BMI&gt;50) remains a high risk undertaking with &gt;5% operative mortality being reported when
      commonly performed bariatric surgical approaches are employed. By contrast, laparoscopic
      two-stage approach has resulted in excellent weight loss, minimal morbidity, and &lt;1%
      mortality.

      Availability of blood samples and biopsies of omental and subcutaneous fat from each of the
      paired bariatric procedures in this protocol will provide a unique opportunity to study key
      issues in human obesity. This study tests the broad hypothesis that there are significant and
      as yet unrecognized differences between the pathobiology of obesity in man and rodents, the
      identification of which may lead to new therapeutic targets. Accordingly, to facilitate
      comparisons with aspects of obesity we have already investigated in animal models, we will 1.
      seek fat depot specific differences in Long Chain Fatty Acid (LCFA) disposition, macrophage
      infiltration and adipokine production in obesity and after surgery-induced weight loss in
      man, and correlate them with the presence/severity of the metabolic syndrome (MetSyn); and
      2., quantify the relative significance and response to weight loss of different mechanisms
      contributing to hepatic steatosis and the elevated triglycerides (TG) and reduced
      High-Density Lipoprotein (HDL) typical of obesity and MetSyn.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Size of Adipocytes</measure>
    <time_frame>4 years</time_frame>
    <description>The mean diameters of omental adipocytes were measured</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Reaction Velocity (Vmax) for Facilitated LCFA Uptake</measure>
    <time_frame>4 years</time_frame>
    <description>The Vmax for facilitated Long Chain Fatty Acids (LCFA) uptake by omental adipocytes was measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Reaction Velocity (Vmax) for Fatty Acid Uptake Relative to Adipocyte Cell Surface Area</measure>
    <time_frame>4 years</time_frame>
    <description>Fatty acid uptake was expressed relative to adipocyte cell surface area [Vmax'(pmol/sec/µm^2) = Vmax/(cell surface area) X 10^8].</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Obesity</condition>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Non-Obese (NO)</arm_group_label>
    <description>Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morbidly Obese (MO)</arm_group_label>
    <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Super-morbidly Obese (SMO)</arm_group_label>
    <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.
10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (second bariatric surgery) of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Initial Surgery</intervention_name>
    <description>NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.
MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.
All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) &amp; fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified.</description>
    <arm_group_label>Non-Obese (NO)</arm_group_label>
    <arm_group_label>Morbidly Obese (MO)</arm_group_label>
    <arm_group_label>Super-morbidly Obese (SMO)</arm_group_label>
    <other_name>Intervention names:</other_name>
    <other_name>NO patients all had one surgery: Abdominal Laparoscopic Surgery. Specific procedure determined by underlying medical condition.</other_name>
    <other_name>MO patients all had one surgery: Abdominal Laparoscopic Bariatric Surgery.</other_name>
    <other_name>All 30 SO patients had an initial Abdominal Laparoscopic Bariatric Surgery.</other_name>
    <other_name>The first 10 SMO patients to meet defined requirements had a second Abdominal Laparoscopic Bariatric Surgery. Details below.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Second Bariatric Surgery</intervention_name>
    <description>A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.</description>
    <arm_group_label>Super-morbidly Obese (SMO)</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples and biopsies of omental and subcutaneous fat.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subject population will be drawn from adults referred for bariatric surgery at New York
        Presbyterian Hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18 - 75 years of age

          -  Scheduled to have two stage bariatric surgery

          -  BMI &gt; 50

        Exclusion Criteria:

          -  Younger than 18 or older than 75 years of age

          -  Underlying cardiac disease or other medical condition that increases the risk of their
             surgical procedure

          -  Pregnancy

          -  Sufficiently diminished mental capacity so as to be unable to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul D Berk, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2008</study_first_submitted>
  <study_first_submitted_qc>May 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2008</study_first_posted>
  <results_first_submitted>December 6, 2012</results_first_submitted>
  <results_first_submitted_qc>February 6, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 11, 2013</results_first_posted>
  <last_update_submitted>July 14, 2013</last_update_submitted>
  <last_update_submitted_qc>July 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Columbia University</investigator_affiliation>
    <investigator_full_name>Paul D. Berk</investigator_full_name>
    <investigator_title>Professor, Department of Medicine, Digestive &amp; Liver Diseases</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>morbid obesity</keyword>
  <keyword>bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients referred to several Divisions of the Department of Surgery at New York Presbyterian Hospital.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Non-Obese (NO)</title>
          <description>Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="P2">
          <title>Morbidly Obese (MO)</title>
          <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="P3">
          <title>Super-morbidly Obese (SMO)</title>
          <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.
10 subjects of the original 30 subjects enrolled into this group received a second bariatric procedure. The remaining 20 subjects of the original 30 subjects did not continue on to the second phase (initial bariatric surgery) of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Surgery</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Operation</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">No medical reason, and no study-related reason for non-obese pts to have a second procedure.</participants>
                <participants group_id="P2" count="0">No medical reason, and none for the goals of the study, for MO pts to have a second procedure .</participants>
                <participants group_id="P3" count="10">As predicted, only 10 SMO patients medically required a second operation, and thus met study goals.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Non-Obese (NO)</title>
          <description>Non obese patients. Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="B2">
          <title>Morbidly Obese (MO)</title>
          <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="B3">
          <title>Super-morbidly Obese (SMO)</title>
          <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" spread="0"/>
                    <measurement group_id="B2" value="10" spread="0"/>
                    <measurement group_id="B3" value="30" spread="0"/>
                    <measurement group_id="B4" value="50" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0" spread="0"/>
                    <measurement group_id="B2" value="0" spread="0"/>
                    <measurement group_id="B3" value="0" spread="0"/>
                    <measurement group_id="B4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Size of Adipocytes</title>
        <description>The mean diameters of omental adipocytes were measured</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese (NO)</title>
            <description>Non obese patients. Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Morbidly Obese (MO)</title>
            <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Super-morbidly Obese (SMO)</title>
            <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Size of Adipocytes</title>
          <description>The mean diameters of omental adipocytes were measured</description>
          <units>µm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4" spread="16.1"/>
                    <measurement group_id="O2" value="99.0" spread="24.0"/>
                    <measurement group_id="O3" value="103.0" spread="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Reaction Velocity (Vmax) for Facilitated LCFA Uptake</title>
        <description>The Vmax for facilitated Long Chain Fatty Acids (LCFA) uptake by omental adipocytes was measured.</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese (NO)</title>
            <description>Non obese patients. Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Morbidly Obese (MO)</title>
            <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Super-morbidly Obese (SMO)</title>
            <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reaction Velocity (Vmax) for Facilitated LCFA Uptake</title>
          <description>The Vmax for facilitated Long Chain Fatty Acids (LCFA) uptake by omental adipocytes was measured.</description>
          <units>pmol/sec</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="1.8"/>
                    <measurement group_id="O2" value="20.9" spread="4.1"/>
                    <measurement group_id="O3" value="68.7" spread="9.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Reaction Velocity (Vmax) for Fatty Acid Uptake Relative to Adipocyte Cell Surface Area</title>
        <description>Fatty acid uptake was expressed relative to adipocyte cell surface area [Vmax’(pmol/sec/µm^2) = Vmax/(cell surface area) X 10^8].</description>
        <time_frame>4 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Non-Obese (NO)</title>
            <description>Non obese patients. Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O2">
            <title>Morbidly Obese (MO)</title>
            <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
          <group group_id="O3">
            <title>Super-morbidly Obese (SMO)</title>
            <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Reaction Velocity (Vmax) for Fatty Acid Uptake Relative to Adipocyte Cell Surface Area</title>
          <description>Fatty acid uptake was expressed relative to adipocyte cell surface area [Vmax’(pmol/sec/µm^2) = Vmax/(cell surface area) X 10^8].</description>
          <units>pmol/sec/μm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.39"/>
                    <measurement group_id="O2" value="1.24" spread="0.36"/>
                    <measurement group_id="O3" value="3.21" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Non-Obese (NO)</title>
          <description>Non obese patients. Patients with a BMI &lt; 29.9 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="E2">
          <title>Morbidly Obese (MO)</title>
          <description>Patients with a BMI &gt; 40.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
        <group group_id="E3">
          <title>Super-morbidly Obese (SMO)</title>
          <description>Patients with a BMI &gt; 50.0 scheduled for clinically indicated laparoscopic abdominal surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul D. Berk, MD</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>2120-305-4491</phone>
      <email>pb2158@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

